Bringing better medicine to patients

Science sourced worldwide

Many patients in China suffer from a range of chronic eye conditions. This large patient population is expected to continue to grow over the coming years as a result of the rapid aging of the population, overuse of electronics, air pollution and other risk factors for ophthalmic diseases.



TP-03 (lotilaner ophthalmic solution, 0.25%) is a novel, investigational therapeutic designed to target and eradicate Demodex mites. It is a potent, non-competitive antagonist of insect and arachnid GABA-Cl channels and a highly lipophilic molecule, which may promote its uptake in the oily sebum of the hair follicle where the mites reside.

Phase 3